HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mechanisms underlying transient receptor potential ankyrin 1 (TRPA1)-mediated hyperalgesia and edema.

Abstract
The aim of this study was to investigate the mechanisms that contribute to hyperalgesia and edema induced by TRPA1 activation. The injection of allyl isothiocyanate (AITC, 50, 100, or 300 µg/paw) into the rat's hind paw induced dose and time-dependent hyperalgesia and edema, which were blocked by the selective TRPA1 antagonist, HC 030031 (1,200 µg/paw), or by treatment with antisense oligodeoxynucleotide (four daily intrathecal injections of 5 nmol). These results demonstrate that the hyperalgesia and edema induced by AITC depend on TRPA1 activation. AITC-induced hyperalgesia and edema were significantly reduced by treatment with neurokinin 1 (L-703,606, 38 µg/paw) or calcitonin gene-related peptide (CGRP8-37 , 5 µg/paw) receptor antagonists, with a mast cell degranulator (compound 48/80, four daily injections of 1, 3, 10, and 10 µg/paw) or with H1 (pyrilamine, 400 µg/paw), 5-HT1A (wAy-100,135, 450 µg/paw) or 5-HT3 (tropisetron, 450 µg/paw) receptor antagonists. Pre-treatment with a selectin inhibitor (fucoidan, 20 mg/kg) significantly reduced AITC-induced hyperalgesia, edema, and neutrophil migration. Finally, a cyclooxygenase inhibitor (indomethacin, 100 µg/paw), a β1 (atenolol, 6 µg/paw) or a β2 (ICI 118, 551, 1.5 µg/paw) adrenoceptor antagonist also significantly reduced AITC-induced hyperalgesia and edema. Together, these results demonstrate that TRPA1 mediates some of the key inflammatory mechanisms, suggesting a key role of this receptor in pain and inflammation.
AuthorsAndressa Perin-Martins, Juliana Maia Teixeira, Claudia H Tambeli, Carlos Amílcar Parada, Luana Fischer
JournalJournal of the peripheral nervous system : JPNS (J Peripher Nerv Syst) Vol. 18 Issue 1 Pg. 62-74 (Mar 2013) ISSN: 1529-8027 [Electronic] United States
PMID23521647 (Publication Type: Journal Article)
Copyright© 2013 Peripheral Nerve Society.
Chemical References
  • 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide
  • Acetanilides
  • Oligodeoxyribonucleotides, Antisense
  • Peptide Fragments
  • Piperazines
  • Purines
  • Quinuclidines
  • Serotonin Antagonists
  • TRPA1 Cation Channel
  • TRPC Cation Channels
  • Trpa1 protein, rat
  • calcitonin gene-related peptide (8-37)
  • WAY 100135
  • L 703606
  • Peroxidase
  • Calcitonin Gene-Related Peptide
Topics
  • Acetanilides (toxicity)
  • Analysis of Variance
  • Animals
  • Calcitonin Gene-Related Peptide (pharmacology)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Edema (chemically induced, complications, drug therapy)
  • Extremities (pathology)
  • Gene Expression Regulation (drug effects)
  • Hyperalgesia (chemically induced, drug therapy, metabolism)
  • Male
  • Oligodeoxyribonucleotides, Antisense (therapeutic use)
  • Peptide Fragments (pharmacology)
  • Peroxidase (metabolism)
  • Piperazines (pharmacology)
  • Purines (toxicity)
  • Quinuclidines (pharmacology)
  • Rats
  • Rats, Wistar
  • Serotonin Antagonists (pharmacology)
  • TRPA1 Cation Channel
  • TRPC Cation Channels (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: